undamentalytics Newsletter

Foghorn Therapeutics Inc. insider trading

Every open-market purchase and sale by Foghorn Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Foghorn Therapeutics Inc.’s insiders pay?

From August 18, 2023 to March 12, 2024, 2 insiders reported 0 open-market purchases and 2 sales not made under a pre-set plan in Foghorn Therapeutics Inc. After sales, the shares moved −37.1% against the index over 12 months (a negative figure means selling was the right call).

Foghorn Therapeutics Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Agresta Samuel Chief Medical Officer 0 — — 1 −30.9% (1) August 18, 2023
Cavalie Fanny Chief Strategy/Bus Ops Officer 0 — — 1 −43.3% (1) March 12, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Foghorn Therapeutics Inc. · Funds · Politicians